By Michele Maatouk
Date: Tuesday 07 Apr 2026
(Sharecast News) - California-based Gilead Sciences said on Tuesday that it has agreed to buy German clinical stage biotechnology group Tubulis for up to $5bn.
| Currency | US Dollars |
| Share Price | $ 168.08 |
| Change Today | $ 0.13 |
| % Change | 0.08 % |
| 52 Week High | $174.14 |
| 52 Week Low | $118.30 |
| Volume | 3,637,695 |
| Shares Issued | 1,241.00m |
| Market Cap | $208,587m |
| Beta | 0.01 |
| RiskGrade | 120 |
| Strong Buy | 8 |
| Buy | 15 |
| Neutral | 4 |
| Sell | 1 |
| Strong Sell | 0 |
| Total | 28 |

| Time | Volume / Share Price |
| 15:59 | 100 @ $168.06 |
| 15:59 | 136 @ $168.07 |
| 15:59 | 100 @ $168.07 |
| 15:59 | 136 @ $168.06 |
| 15:59 | 136 @ $168.07 |
You are here: research